Navigation Links
SyntheMed Receives Canadian Approval for REPEL-CV(R)
Date:7/14/2008

ISELIN, N.J., July 14 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products and other surgical implants, announced today that REPEL-CV(R), the company's bioresorbable adhesion barrier film for the reduction of adhesions following cardiac surgery, has received Health Canada approval for use in pediatric patients who undergo open heart surgery. REPEL-CV will be marketed throughout Canada by Force3 Medicale, Inc., a Montreal-based distributor of cardiac surgery products. Marc Sportsman, SyntheMed's Vice President of Sales, stated, "We are pleased to receive the Health Canada approval which allows us to further expand the international distribution of REPEL-CV."

SyntheMed was previously granted CE Mark approval to market REPEL-CV in most international markets for use in all patients who undergo open heart surgery and is being sold through a network of independent distributors. In November 2007, SyntheMed received an Approval Letter from the US FDA stating the REPEL-CV would be approved for use in pediatric patients pending satisfactory completion of field inspections. This process is ongoing as are discussions with the FDA on the requirements for expansion of the indication for REPEL-CV from pediatric patients to all patients who undergo cardiac surgery.

About Adhesions

Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surrounding tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the length, cost and risk of the surgical procedure.

About REPEL-CV

REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions (scar tissue) that form between the surface of the heart and opposing tissue surfaces following the surgical procedure. REPEL-CV is designed to provide the therapeutic benefit and then degrade so that it is cleared from the body. REPEL-CV represents the first in a series of anti-adhesion products under development that are based on the Company's proprietary polymer technology.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products, and other surgical implants. The Company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology.

Statements in this Press Release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the Company's efforts to obtain and maintain FDA and other required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the Company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... NEW YORK , May 4, 2016 ... Size, Share, Development, Growth and Demand Forecast to 2022 - ... End User (Hospital, Diagnostic Center and Others)" by P&S Market ... at $4,894.3 million in 2015, and it is expected to ... slice type, the high slice type segment is expected to ...
(Date:5/4/2016)... D.C. , May 4, 2016 ... member companies concluded a series of free workshops ... in global requirements for Good Distribution ... of quality assurance which ensures that products are consistently stored, ... the marketing authorization (MA) or product specification. Only a ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Multiple Myeloma Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Multiple Myeloma market valuations and forecast, ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... The University of Western States ... the 2016 National SACA Leadership Conference on the Portland campus September 23-25. The ... to come together and develop skills to be future leaders in the profession. ...
(Date:5/5/2016)... ... ... Vitenas Cosmetic Surgery has been named as one of the eight recipients ... and the Academy of Architecture for Health. The building, brainchild of founder Paul Vitenas, ... in October of 2014. , The prestigious Healthcare Design Awards are ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dr. Benjamin Stong of Kalos ... loss treatment. Dr. Stong is double board certified and the only facial plastic ... treatment of hair loss. Non-surgical therapies such as stem cells can be used to ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... In honor ... firm, is encouraging people all over the United States to thank a nurse who's ... Aya Healthcare will donate $5 to the American Red Cross of San Diego/Imperial Counties ...
(Date:5/5/2016)... ... ... Chronic stress can have a silent, yet dangerous, impact on men’s heart ... increase inflammation, both of which raise the risk of heart attack and even stroke,” ... Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to other issues that indirectly ...
Breaking Medicine News(10 mins):